interplonal Application No PC1/CA2004/000662

		PCT/CA200	04/000662		
A. CLASSII IPC 7	FICATION OF SUBJECT MATTER A61K31/716 A61K35/78 A61P17/0	0			
According to	o International Patent Classification (IPC) or to both national classification	ation and IPC			
B. FIELDS	SEARCHED				
IPC 7	ocumentation searched (classification system followed by classificate A61K A61P	on symbols)			
Documentat	lon searched other than minimum documentation to the extent that s	uch documents are included in the fields s	earched		
	ata base consulted during the international search (name of data bas ternal, WPI Data, PAJ, BIOSIS, EMBAS		d)		
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT				
Category °	Citation of document, with Indication, where appropriate, of the rela	evant passages	Relevant to claim No.		
X	WO 02/43719 A (WEISSMAN GLENN H) 6 June 2002 (2002-06-06) example 2		1,2,8,9		
x	WO 00/67626 A (FIELDER DAVID ; CE (CA); REDMOND MARK J (CA)) 16 November 2000 (2000-11-16) example 9	APRO INC	1-4		
x	US 5 980 918 A (KLEIN BARBARA K) 9 November 1999 (1999-11-09) the whole document		1,8,9		
X	WO 01/74300 A (BRENNEN MEDICAL IN 11 October 2001 (2001-10-11) page 3, lines 1-4 page 8, lines 17-22	IC)	1,8,9		
	-	-/- -			
X Furti	her documents are listed in the continuation of box C.	X Patent family members are listed	lin annex.		
° Special ca	itegones of cited documents:				
"A" docume consid "E" earlier o	ont defining the general state of the art which is not lered to be of particular relevance document but published on or after the international	 "T" later document published after the im or priority date and not in conflict wit cited to understand the principle or ti invention "X" document of particular relevance; the 	h the application but heory underlying the		
filing d	ant which may throw doubts on priority claim(s) or	cannot be considered novel or cannot involve an inventive step when the	ot be considered to		
which citation 'O' docume	is cited to establish the publication date of another n or other special reason (as specified) ant referring to an oral disclosure, use, exhibition or	"Y" document of particular relevance; the cannot be considered to involve an i- document is combined with one or n	claimed invention nventive step when the nore other such docu-		
P docume	means ent published prior to the international filling date but han the priority date claimed	ments, such combination being obvi in the art. *&* document member of the same pater			
Date of the	actual completion of the international search	Date of mailing of the international se	arch report		
2	4 September 2004	11/10/2004			
Name and n	nailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk	Authorized officer			
1	Tel. (+31-70) 340-2040, Tx. 31 651 epo ni, Fax: (+31-70) 340-3016	Pacreu Largo, M			

Internal Application No PC1/CA2004/000662

		PCT7CA2004/000662
C.(Continua Category *	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Category	Cration of normant, with indication, where appropriate, or the report it bassages	neevall to claim to.
X	ESTRADA A ET AL: "Effect of administration of oat beta-glucan on immune parameters of healthy and immunosuppressed beef steers." CANADIAN JOURNAL OF VETERINARY RESEARCH = REVUE CANADIENNE DE RECHERCHE VETERINAIRE. OCT 1999, vol. 63, no. 4, October 1999 (1999-10), pages 261-268, XP002297977 ISSN: 0830-9000 page 263	1,6,8,9
P,X	WO 03/054077 A (CEAPRO INC ; FIELDER DAVID A (CA); REDMOND MARK J (CA)) 3 July 2003 (2003-07-03) page 8, lines 29-32; claims 1,10-14	1,5-11
A	ESTRADA ALBERTO ET AL: "Immunomodulatory activities of oat beta-glucan in vitro and in vivo" MICROBIOLOGY AND IMMUNOLOGY, vol. 41, no. 12, 1997, pages 991-998, XP009036004 ISSN: 0385-5600 abstract	1-27
Α	CHEUNG NAI-KONG V ET AL: "Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies." CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 51, no. 10, November 2002 (2002-11), pages 557-564, XP002297978 ISSN: 0340-7004 abstract	1-27
Α	YUN C-H ET AL: "'beta!-Glucan, extracted from oat, enhances disease resistance against bacterial and parasitic infections" FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY 21 FEB 2003 NETHERLANDS, vol. 35, no. 1, 21 February 2003 (2003-02-21), pages 67-75, XP002297979 ISSN: 0928-8244 abstract -/	1-27

Internal Application No PCT/CA2004/000662

		PCT/CA2004/000662		
C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT			
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
A	BRAATEN J T ET AL: "OAT BETA-GLUCAN REDUCES BLOOD CHOLESTEROL CONCENTRATION IN HYPERCHOLESTEROLEMIC SUBJECTS" EUROPEAN JOURNAL OF CLINICAL NUTRITION, XX, XX, vol. 48, July 1994 (1994-07), pages 465-474, XP001027909 abstract	1-27		
	US 5 518 710 A (BHATTY RATTAN S) 21 May 1996 (1996-05-21) the whole document	1-27		

nformation on patent family members

International Application No PC1/CA2004/000662

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 0243719	Α	06-06-2002	AU	1994502	Α	11-06-2002
	•		WO	0243719	A2	06-06-2002
			ÜS	2002102316	A1	01-08-2002
WO 0067626	A	16-11-2000	AU	767424	B2	13-11-2003
			AU	5393200	Α	21-11-2000
			CA	2368218	A1	16-11-2000
			WO	0067626	A2	16-11-2000
			ΕP	1185241		13-03-2002
			JP	2002544145	T	24-12-2002
US 5980918	A	09-11-1999	CA	2304815	A1	06-05-1999
			EP	1024784	A1	09-08-2000
			JP	2001520982	T	06-11-2001
			WO	9921531		06-05-1999
			US	6168799	B1	02-01-2001
WO 0174300	Α	11-10-2001	AU	5087501	A	15-10-2001
			EP	1267795	A1	02-01-2003
			MO	0174300	A1	11-10-2001
			US	2004005364	A1	08-01-2004
WO 03054077	Α	03-07-2003	WO	03054077		03-07-2003
			CA	2467378	A1	03-07-2003
			EP	1453909	A1	08-09-2004
US 5518710	Α	21-05-1996	NONE			